The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity check: The target is human MED13L, UniProt Q71F56, also known as THRAP2/TRAP240L/KIAA1025, a Mediator complex subunit 13 family member. The organism is Homo sapiens, and MED13L is a paralog of MED13. This matches the user-provided UniProt identity and literature below (siavrienė 2023; Campbell/Bain/Doyle GeneReviews excerpt, 2025) (siavriene2023molecularandfunctional pages 9-10, campbell2025med13lsyndromea pages 12-15).

Table: Compact summary table of human MED13L (Q71F56) covering identity, domains, Mediator/CKM role, structural and functional insights, regulation, disease links, phenotype frequencies, and translational resources with primary 2023–2024 sources for rapid reference.

Comprehensive research report

1) Key concepts and definitions (current understanding)
- Definition and complex membership: MED13L encodes Mediator of RNA polymerase II transcription subunit 13-like, a non-enzymatic subunit of the Mediator complex’s cyclin-dependent kinase module (CKM). The vertebrate CKM comprises CDK8/19, cyclin C (CCNC), MED12/MED12L, and MED13/MED13L. MED13L is paralogous to MED13 and functions as a tether that links the CKM to the core Mediator (cMED), modulating Pol II engagement and transcriptional programs (Jun 2023; Jul 2024 preprint) (siavriene2023molecularandfunctional pages 9-10, chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42). URL: https://doi.org/10.3390/medicina59071225 (Jun 2023); https://doi.org/10.1101/2024.07.01.601608 (posted Jul 3, 2024).
- Domain architecture: MED13/13L exhibits an Argonaute-like fold with N/PAZ/MID(=MedPIWI)/PIWI elements and large intrinsically disordered regions (IDRs). Discrete Med13_N, MID/MedPIWI, and Med13_C modules are recognized; the MedPIWI/MID core is implicated in CKM regulatory switching (Jul 2024 preprint; Jun 2023) (chen2024structuralbasisof pages 27-34, siavriene2023molecularandfunctional pages 9-10). URL: https://doi.org/10.1101/2024.07.01.601608; https://doi.org/10.3390/medicina59071225.
- Cellular localization and expression: MED13L is broadly expressed across human tissues, with notable expression in brain regions and fibroblasts; it localizes primarily to the nucleus consistent with Mediator function, with additional reports of synaptic localization in neurons (Jun 2023; Feb 2023) (siavriene2023molecularandfunctional pages 9-10, hamada2023med13landits pages 18-19). URL: https://doi.org/10.3390/medicina59071225; https://doi.org/10.1111/jnc.15783.
- Primary biochemical role: MED13L is an adaptor/tether within the CKM that influences the Mediator–Pol II interface and promoter-proximal events; it does not catalyze enzymatic reactions. Through CKM placement, MED13L helps control access of Pol II and cofactors (e.g., MED26), thereby affecting initiation and pause-release programs (Jul 2024 preprint) (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42). URL: https://doi.org/10.1101/2024.07.01.601608.

2) Recent developments and latest research (priority 2023–2024)
- Cryo-EM/XL-MS placement of MED13/MED13L within CKM and on cMED: Human CKM docked onto the cMED Hook was resolved by cryo-EM; crosslinks indicate that MED13/13L C-terminal IDRs contact the cMED Hook and overlap the Pol II/MED26 binding surfaces on cMED. This supports a mechanism where MED13/13L IDRs can occlude cMED–Pol II/ MED26 interactions, gating cMED–PIC assembly; dissociation/repositioning of MED13/13L facilitates Pol II engagement. Additional structural observations include putative zinc-binding features in MED13 and an active CDK8 T-loop conformation within the docked CKM (bioRxiv, posted Jul 3, 2024) (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42). URL: https://doi.org/10.1101/2024.07.01.601608.
- Neuronal development: In vivo studies show MED13L is required for dendritic development of cortical excitatory neurons; disease-associated variants impact subcellular distribution/stability and reduce dendrite number/length or spine maturation. Knockdown impairs dendritic growth, rescued by RNAi-resistant MED13L (Journal of Neurochemistry, Feb 2023) (hamada2023med13landits pages 18-19). URL: https://doi.org/10.1111/jnc.15783.
- Human genetics—novel deletions and functional validation: A 2023 study characterized a novel intragenic 12q24.21 deletion (exons 3–10) producing a frameshift and predicted truncation that disrupts Med13_N and removes MedPIWI/Med13_C, consistent with haploinsufficiency. Patient fibroblasts had markedly reduced MED13L protein; CRISPR-Cas9 knockout in control fibroblasts decreased viability, and expression analyses indicated perturbation of Wnt/FGF signaling and Rb/E2F-related programs (Medicina, Jun 2023) (siavriene2023molecularandfunctional pages 9-10, siavriene2023molecularandfunctional pages 13-14). URL: https://doi.org/10.3390/medicina59071225.
- Translational roadmap: The MED13L Foundation Strategic Research Plan (Therapeutic Advances in Rare Disease, 2024) synthesizes literature and outlines clinical trial readiness tools, natural history efforts, and priorities toward therapies for MED13L syndrome (2024) (clevenger2025diseaseconceptmodela pages 63-64). URL: https://doi.org/10.1177/26330040241290252.

3) Current applications and real-world implementations
- Clinical diagnostics: Exome/genome sequencing (including CNV analysis) and RNA studies to detect intragenic deletions, truncating variants, and missense changes are standard approaches for suspected MED13L syndrome. Family testing for mosaicism is recommended due to documented germline mosaicism leading to recurrence risk (case evidence 2022) (campbell2025med13lsyndromea pages 12-15, yi2020reportofa pages 10-10). URL: https://doi.org/10.1101/mcs.a006124 (Oct 2022); https://doi.org/10.1186/s13052-020-00847-y (Jul 2020).
- Functional cell assays: Western blot quantification of MED13L, CRISPR-mediated knockdown/knockout in patient/control fibroblasts, and transcriptome analyses to confirm haploinsufficiency consequences and pathway dysregulation (Jun 2023) (siavriene2023molecularandfunctional pages 9-10). URL: https://doi.org/10.3390/medicina59071225.
- Research resources and advocacy: The 2024 MED13L Foundation plan provides a community-facing framework to coordinate natural history, biomarker development, and preclinical models for therapy development (2024) (clevenger2025diseaseconceptmodela pages 63-64). URL: https://doi.org/10.1177/26330040241290252.

4) Expert opinions and analysis from authoritative sources
- GeneReviews-style synthesis (Campbell, Bain, Doyle excerpt, 2025): MED13L and MED13 act as the protein tether linking CKM to Mediator. Pathogenic variants cause transcriptional defects and may perturb cyclin C localization; most disease-causing variants are de novo and consistent with haploinsufficiency, though severe missense alleles can produce more pronounced phenotypes. Recommendation: consider parental mosaicism in recurrence risk (2025) (campbell2025med13lsyndromea pages 12-15).
- Structural analysis (2024 preprint): The CKM–cMED arrangement rationalizes how MED13/13L IDRs regulate cMED’s ability to bind Pol II/MED26 and to reposition CKM to act on pausing factors, aligning molecular placement with control of initiation/pausing/elongation transitions (posted Jul 2024) (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42). URL: https://doi.org/10.1101/2024.07.01.601608.
- Neurobiology (2023): MED13L is required cell-autonomously in cortical neurons for dendritic growth/spine maturation, providing a mechanistic link to neurodevelopmental phenotypes in patients (Feb 2023) (hamada2023med13landits pages 18-19). URL: https://doi.org/10.1111/jnc.15783.

5) Relevant statistics and data from recent studies
- Frequency of clinical features (2023 cohort): Near-universal developmental delay/intellectual disability and speech impairment; hypotonia and dysmorphic/ophthalmologic findings frequent; congenital heart defects in about 20.8% (15/72) in the literature summarized within the 2023 report (Jun 2023) (siavriene2023molecularandfunctional pages 9-10). URL: https://doi.org/10.3390/medicina59071225.
- Variant spectrum: Heterozygous loss-of-function (nonsense, frameshift, canonical splice-site), intragenic deletions, and missense variants; de novo events predominate; documented parental germline mosaicism (2022 case study) (yi2020reportofa pages 10-10). URL: https://doi.org/10.1101/mcs.a006124 (Oct 2022).

Mechanistic integration
- Role in transcription and pathways: As a CKM tether, MED13L’s IDRs can restrict or allow cMED interaction with Pol II/MED26, shaping promoter engagement and pause control. Human cellular models indicate MED13L loss alters Wnt and FGF pathways and Rb/E2F cell-cycle modules, consistent with CKM’s broad transcriptional regulatory scope (2023–2024) (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42, siavriene2023molecularandfunctional pages 9-10).
- Regulation and stress responses: CKM components exhibit stress-responsive dynamics. Prior work implicates SCF-dependent proteolysis of Med13 family members and CKM-driven cyclin C relocalization with mitochondrial effects; patient-focused reviews note cyclin C mislocalization in MED13L pathogenic settings (2018; 2025 excerpt) (campbell2025med13lsyndromea pages 12-15). While specific human E3 ligase targeting of MED13L was not detailed in the provided 2023–2024 evidence, the conserved paradigm supports regulated CKM composition and localization.
- Neurodevelopment and heart development: Mouse and human cellular data support key roles of MED13L in neuronal differentiation, dendritic arborization, and brain development; human clinical cohorts consistently show neurodevelopmental phenotypes, and congenital heart defects are present in a subset (~20% in one 2023 dataset), in line with Mediator’s roles in developmental transcription programs (Feb 2023; Jun 2023) (hamada2023med13landits pages 18-19, siavriene2023molecularandfunctional pages 9-10).

Clinical implications and translational directions (2024 focus)
- Diagnostic recommendations: Employ exome/genome sequencing with CNV detection; consider RNA analysis for splice-impacting variants; test parents for mosaicism to refine recurrence risk (2022–2025) (yi2020reportofa pages 10-10, campbell2025med13lsyndromea pages 12-15).
- Therapeutic outlook: The 2024 MED13L Foundation plan outlines priorities including natural history studies, standardized outcome measures, and preclinical model development to enable future trials (2024) (clevenger2025diseaseconceptmodela pages 63-64). URL: https://doi.org/10.1177/26330040241290252.

Conclusions
MED13L (Q71F56) is a human Mediator CKM tether with Ago-like domain architecture whose IDRs regulate cMED–Pol II engagement and promoter-proximal control. Recent structural work provides a mechanistic basis for MED13/13L gating of Pol II/MED26 access, while 2023 neuronal studies show MED13L’s necessity for dendritogenesis. Human genetics consolidates MED13L haploinsufficiency syndrome with predominantly de novo variants, documented mosaicism, and frequent neurodevelopmental features with variable cardiac involvement. Translational frameworks are being established to advance clinical research and therapeutic readiness (chen2024structuralbasisof pages 27-34, chen2024structuralbasisof pages 39-42, hamada2023med13landits pages 18-19, siavriene2023molecularandfunctional pages 9-10, yi2020reportofa pages 10-10, clevenger2025diseaseconceptmodela pages 63-64, campbell2025med13lsyndromea pages 12-15).

References

1. (siavriene2023molecularandfunctional pages 9-10): Evelina Siavrienė, Gunda Petraitytė, Violeta Mikštienė, Živilė Maldžienė, Aušra Sasnauskienė, Vilmantė Žitkutė, Laima Ambrozaitytė, Tautvydas Rančelis, Algirdas Utkus, Vaidutis Kučinskas, and Eglė Preikšaitienė. Molecular and functional characterisation of a novel intragenic 12q24.21 deletion resulting in med13l haploinsufficiency syndrome. Medicina, 59:1225, Jun 2023. URL: https://doi.org/10.3390/medicina59071225, doi:10.3390/medicina59071225. This article has 8 citations and is from a poor quality or predatory journal.

2. (campbell2025med13lsyndromea pages 12-15): AN Campbell, J Bain, and SJ Doyle. Med13l syndrome. Unknown journal, 2025.

3. (chen2024structuralbasisof pages 27-34): Shin-Fu Chen, Ti-Chun Chao, Hee Jong Kim, Hui-Chi Tang, Subash Khadka, Tao Li, Dung-Fang Lee, Kenji Murakami, Thomas G. Boyer, and Kuang-Lei Tsai. Structural basis of the human transcriptional mediator complex modulated by its dissociable kinase module. bioRxiv, Jul 2024. URL: https://doi.org/10.1101/2024.07.01.601608, doi:10.1101/2024.07.01.601608. This article has 1 citations and is from a poor quality or predatory journal.

4. (chen2024structuralbasisof pages 39-42): Shin-Fu Chen, Ti-Chun Chao, Hee Jong Kim, Hui-Chi Tang, Subash Khadka, Tao Li, Dung-Fang Lee, Kenji Murakami, Thomas G. Boyer, and Kuang-Lei Tsai. Structural basis of the human transcriptional mediator complex modulated by its dissociable kinase module. bioRxiv, Jul 2024. URL: https://doi.org/10.1101/2024.07.01.601608, doi:10.1101/2024.07.01.601608. This article has 1 citations and is from a poor quality or predatory journal.

5. (hamada2023med13landits pages 18-19): Nanako Hamada, Ikuko Iwamoto, and Koh‐ichi Nagata. med13l and its disease‐associated variants influence the dendritic development of cerebral cortical neurons in the mammalian brain. Journal of Neurochemistry, 165:334-347, Feb 2023. URL: https://doi.org/10.1111/jnc.15783, doi:10.1111/jnc.15783. This article has 12 citations and is from a domain leading peer-reviewed journal.

6. (clevenger2025diseaseconceptmodel pages 63-64): KM Clevenger. Disease concept model for med13l syndrome. Unknown journal, 2025.

7. (clevenger2025diseaseconceptmodela pages 63-64): KM Clevenger. Disease concept model for med13l syndrome. Unknown journal, 2025.

8. (siavriene2023molecularandfunctional pages 13-14): Evelina Siavrienė, Gunda Petraitytė, Violeta Mikštienė, Živilė Maldžienė, Aušra Sasnauskienė, Vilmantė Žitkutė, Laima Ambrozaitytė, Tautvydas Rančelis, Algirdas Utkus, Vaidutis Kučinskas, and Eglė Preikšaitienė. Molecular and functional characterisation of a novel intragenic 12q24.21 deletion resulting in med13l haploinsufficiency syndrome. Medicina, 59:1225, Jun 2023. URL: https://doi.org/10.3390/medicina59071225, doi:10.3390/medicina59071225. This article has 8 citations and is from a poor quality or predatory journal.

9. (yi2020reportofa pages 10-10): Zhi Yi, Ying Zhang, Zhenfeng Song, Hong Pan, Chengqing Yang, Fei Li, Jiao Xue, and Zhenghai Qu. Report of a de novo c.2605c > t (p.pro869ser) change in the med13l gene and review of the literature for med13l-related intellectual disability. Italian Journal of Pediatrics, Jul 2020. URL: https://doi.org/10.1186/s13052-020-00847-y, doi:10.1186/s13052-020-00847-y. This article has 16 citations and is from a peer-reviewed journal.

Citations

1. siavriene2023molecularandfunctional pages 9-10
2. chen2024structuralbasisof pages 27-34
3. clevenger2025diseaseconceptmodela pages 63-64
4. yi2020reportofa pages 10-10
5. chen2024structuralbasisof pages 39-42
6. clevenger2025diseaseconceptmodel pages 63-64
7. siavriene2023molecularandfunctional pages 13-14
8. https://doi.org/10.3390/medicina59071225
9. https://doi.org/10.1101/2024.07.01.601608
10. https://doi.org/10.1111/jnc.15783
11. https://doi.org/10.1101/2024.07.01.601608;
12. https://doi.org/10.3390/medicina59071225.
13. https://doi.org/10.3390/medicina59071225;
14. https://doi.org/10.1111/jnc.15783.
15. https://doi.org/10.1101/2024.07.01.601608.
16. https://doi.org/10.1177/26330040241290252.
17. https://doi.org/10.1101/mcs.a006124
18. https://doi.org/10.1186/s13052-020-00847-y
19. https://doi.org/10.3390/medicina59071225,
20. https://doi.org/10.1101/2024.07.01.601608,
21. https://doi.org/10.1111/jnc.15783,
22. https://doi.org/10.1186/s13052-020-00847-y,

MED13L: Mediator Complex Subunit 13-Like – Function and Significance

Mediator Complex and MED13L – Key Concepts

MED13L (Mediator complex subunit 13-like) is a protein component of the Mediator complex, a large multi-protein coactivator that bridges DNA-binding transcription factors to RNA polymerase II (www.genecards.org). By serving as a molecular bridge, Mediator transmits regulatory signals from transcription factors to the basal transcription machinery, facilitating the assembly of the pre-initiation complex and the initiation of gene transcription (www.genecards.org). MED13L is one of ~26 core subunits of human Mediator, and it specifically forms part of the CDK8 kinase module – a four-subunit subcomplex (CDK8 or CDK19 kinase, Cyclin C, MED12 or MED12L, and MED13 or MED13L) that transiently associates with the core Mediator (genesdev.cshlp.org). MED13L is a paralog of MED13 (the original Mediator subunit 13) arising from a gene duplication in vertebrates (www.longdom.org). These two proteins are highly similar and mutually exclusive in the Mediator kinase module: a given Mediator complex incorporates either MED13 or MED13L, but not both simultaneously (pmc.ncbi.nlm.nih.gov). Human MED13L is a very large protein (2,217 amino acids, ~240 kDa) and shares conserved domains with MED13, including an N-terminal Mediator-binding region and a C-terminal “Med13” domain (IPR009401) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). It also contains predicted intrinsically disordered regions (IDRs), which, as discussed below, are crucial for its regulatory function. MED13L is predominantly a nuclear protein, localizing to the nucleus as part of the Mediator complex bound to chromatin, consistent with its role in transcriptional regulation.

Mediator Kinase Module and regulatory role: The CDK8/Cyclin C module (with MED12–MED13 or MED12L–MED13L) can reversibly attach to or detach from the core Mediator. This modulatory association acts as a switch for transcriptional activity (genesdev.cshlp.org). When the kinase module is attached, it can alter Mediator’s conformation and often inhibit or dampen transcription initiation by preventing efficient recruitment of RNA polymerase II to promoters (genesdev.cshlp.org). Conversely, release of the CDK8 module is generally required for Mediator to fully engage RNA Pol II and activate transcription. MED13L (or MED13) plays a pivotal structural role in this switch: it serves as the anchor that links the kinase module to Mediator, via direct contacts with the Mediator core (genesdev.cshlp.org). In essence, MED13/L is the scaffold holding the module in place, and removing MED13/L dissociates the module from Mediator (genesdev.cshlp.org). Consistently, biochemical studies have shown that SCF–Fbw7 ubiquitin ligase targets MED13 and MED13L for degradation, leading to eviction of the CDK8 module from Mediator (genesdev.cshlp.org) (genesdev.cshlp.org). Fbw7 (a tumor suppressor E3 ligase) thus negatively regulates MED13L stability; loss of Fbw7 causes MED13/13L to accumulate and keep the CDK8 module tethered to Mediator (genesdev.cshlp.org). This dynamic control indicates that MED13L levels can tune transcriptional output: degradation of MED13L frees Mediator to interact with Pol II, whereas stabilized MED13L keeps the repressive kinase module engaged (genesdev.cshlp.org). Indeed, a recent Genes & Development study (2013) demonstrated that Fbw7 deficiency increases CDK8-module association with Mediator by preventing MED13/13L turnover (genesdev.cshlp.org). This discovery highlights MED13L as a key node where cellular signaling (e.g. via Fbw7 or other pathways) can modulate global gene expression programs.

Structural Features and Mechanisms in Transcription

The structural basis of MED13L’s function is an area of active research. Both MED13 and MED13L are predicted to contain long disordered segments flanked by structured domains (pmc.ncbi.nlm.nih.gov). Notably, new findings in 2024 revealed that an intrinsically disordered region in MED13 acts as a molecular switch to control Mediator’s interactions (www.sciencedirect.com). This disordered segment can mutually exclusively bind either to RNA polymerase II or to the CDK8 module, thereby toggling Mediator between an “active” state (engaged with Pol II) and an “off” state (bound by the CDK8 module) (www.sciencedirect.com). In other words, when MED13’s IDR permits Pol II engagement, the kinase module must dislodge; when the CDK8 module binds MED13, it sterically occludes Pol II from Mediator (www.sciencedirect.com). Given the high similarity between MED13 and MED13L, it is very likely that MED13L contains a similar IDR-based switch mechanism, though this has been presumed by homology rather than directly shown. This mechanism elegantly explains how Mediator’s activity is regulated on cue: MED13/MED13L function as a gatekeeper, ensuring that Mediator does not activate transcription until appropriate signals prompt module dissociation. This insight came from complementary cryo-EM and biochemical studies in 2024 (Zhao et al. and Chen et al., as summarized in Molecular Cell (www.sciencedirect.com)), and it underscores the critical regulatory role that the MED13L subunit (through its disordered region) plays in controlling gene expression timing.

Beyond its role as a structural tether, MED13L also contributes to chromatin regulation and transcription elongation via the kinase module. The CDK8/CycC kinase can phosphorylate transcription factors and chromatin proteins, influencing transcriptional pause-release and enhancer activity (genesdev.cshlp.org). MED13L, by recruiting this module, indirectly affects these processes. For instance, the CDK8 module has been shown to modify histones and interact with elongation factors (genesdev.cshlp.org), meaning MED13L’s presence could impact how genes are turned on not only at initiation, but during transcript elongation as well. It’s also noteworthy that Mediator subunits like MED13L often interact with other co-regulators. Proteomic analyses of MED13L-containing Mediator complexes have identified partners beyond the core Mediator, hinting at broader networks. A recent 2023 proteomics study found that MED13L can associate with proteins such as FBXL19 (another F-box protein) and TASP1 (a protease involved in chromatin protein processing), among others (pmc.ncbi.nlm.nih.gov). While the functional consequences of these interactions are still being unraveled, they suggest that MED13L might integrate signals from protein turnover pathways or chromatin-modifying enzymes to fine-tune transcription. In summary, MED13L’s structure (modular domains with IDRs) and its ability to recruit regulatory complexes position it as a critical mediator of Mediator, controlling when and how efficiently Pol II initiates transcription at target genes.

Biological Functions and Pathways

Neurodevelopment and Brain Function

MED13L has a pronounced role in brain development. Genetic analyses first linked MED13L haploinsufficiency to neurodevelopmental disorders, and recent experimental evidence has confirmed its importance in the developing brain (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In 2023, Li et al. generated a Med13l-knockout mouse to model MED13L syndrome (pmc.ncbi.nlm.nih.gov). Homozygous Med13l knockout was embryonically lethal, with mice dying at birth and exhibiting markedly reduced brain size and cortical thickness (pmc.ncbi.nlm.nih.gov). Heterozygous knockout mice (Med13l+/–), which mimic the human syndrome (caused by one nonfunctional allele), survived but showed impaired motor skills, learning and memory deficits, and anxiety, paralleling the intellectual disability and developmental delays observed in human patients (pmc.ncbi.nlm.nih.gov). Closer examination of the developing cortex revealed that MED13L is required for proper cortical neurogenesis: embryos lacking one copy of Med13l had fewer mature neurons and abnormal neural progenitor differentiation (pmc.ncbi.nlm.nih.gov). Single-cell RNA sequencing and proteomic profiling of knockout embryonic brains indicated that MED13L acts as a “transcriptional priming” factor for neurogenesis genes (pmc.ncbi.nlm.nih.gov). In other words, MED13L helps poise key neuronal genes for activation at the right time during cortical development. Many genes governing neuron maturation and dendrite outgrowth were under-expressed or delayed in the absence of MED13L (pmc.ncbi.nlm.nih.gov). Consistently, neurons in Med13l-deficient mice showed simplified dendritic arbors and immature morphology (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These findings suggest that MED13L normally orchestrates transcriptional programs that drive progenitors to exit the cell cycle and differentiate into neurons. Without sufficient MED13L, the timing and extent of neuron differentiation are disrupted, leading to microcephaly and cognitive deficits. This mechanistic insight aligns with clinical genetics: children with MED13L mutations often have significant speech and motor delays, reflecting disruption of neural developmental pathways (pubmed.ncbi.nlm.nih.gov). In summary, MED13L is crucial for brain development, ensuring that neuronal genes are activated when needed and neural circuits form properly.

Cardiac Development and Metabolic Regulation

MED13L is equally critical in the heart, both during embryogenesis and in adult cardiac physiology. The gene’s importance first came to light when heterozygous MED13L mutations were found in patients with congenital heart defects. In particular, MED13L haploinsufficiency can cause conotruncal heart malformations such as dextro-transposition of the great arteries (TGA), where the major arteries are misconnected (www.genecards.org) (pmc.ncbi.nlm.nih.gov). Early case studies of MED13L-disrupted patients noted TGA in some, alongside intellectual disability, suggesting a syndrome affecting heart and brain development (pubmed.ncbi.nlm.nih.gov). However, many MED13L variant carriers have mild or no structural heart defects; instead they present with a syndromic form of developmental delay with or without cardiac anomalies (pubmed.ncbi.nlm.nih.gov). This indicates MED13L’s role in the heart is significant but can be variable – likely depending on the specific mutation and genetic background. Supporting a direct role in cardiogenesis, animal models have shown that MED13L (and its paralog MED13) regulate cardiac gene expression. MED13L is highly expressed in the developing heart, and loss of Med13l in model organisms leads to embryonic cardiac abnormalities (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). A 2021 review highlighted MED13L as “crucial for neurocardiac development,” noting that disruptions in MED13L are implicated in a range of congenital heart diseases beyond TGA, including ventricular septal defects and coarctation of the aorta (pmc.ncbi.nlm.nih.gov). Notably, a duplication of the MED13L gene (leading to excess MED13L) has also been associated with heart defects (like aortic coarctation) (pmc.ncbi.nlm.nih.gov), implying that cardiac development is sensitive to MED13L dosage in both directions (too little or too much can be deleterious).

In the adult heart, MED13L and MED13 serve partially redundant functions to maintain normal cardiac physiology. Knockout mouse studies in 2025 by Henry et al. investigated the roles of these two Mediator subunits in the postnatal heart. Mice lacking MED13 specifically in cardiomyocytes develop cardiac dysfunction, but if MED13L is still present, the heart can partially compensate (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). However, when both Med13 and Med13l were ablated in adult mouse hearts, the result was fatal dilated cardiomyopathy: animals exhibited severe heart failure and 100% mortality within 10 weeks of gene deletion (pmc.ncbi.nlm.nih.gov). The combined knockout hearts showed drastic changes in transcription profiles of metabolic and contractile genes, illustrating that MED13 and MED13L together sustain the baseline gene-expression networks required for cardiac contractility and structure (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Interestingly, only a small subset of genes misregulated by MED13 loss alone overlapped with those misregulated in the double knockout, suggesting that MED13L can compensate for many of MED13’s functions in the heart (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Nonetheless, each protein also has some unique target genes, indicating both redundancy and specialization** (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Overall, these data from animal models confirm that MED13L is essential for cardiac gene regulation – from embryonic heart patterning to adult metabolic homeostasis.

Mechanistically, MED13L influences metabolic signaling in the heart via its role in transcription. Research has uncovered a link between the Mediator kinase module (which includes MED13L) and nuclear receptor signaling pathways that govern cardiac metabolism (pmc.ncbi.nlm.nih.gov). For example, thyroid hormone and other nuclear hormone receptors rely on coactivators like Mediator to regulate genes involved in energy usage. MED13L (historically named “Thyroid hormone receptor-associated protein 2” or TRAP240-like) was initially identified as part of a thyroid hormone receptor-binding complex, hinting at a role in thyroid hormone–mediated gene expression. Consistent with this, recent studies suggest MED13/MED13L in cardiomyocytes can modulate systemic metabolism. Zhou et al. (2021) reported that Mediator subunit 13 influences expression of metabolic genes, and altering MED13 levels in mouse hearts can affect body-wide energy homeostasis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In Drosophila, the MED13 ortholog was shown to work with Wingless (Wnt) signaling in muscle to control fat metabolism and obesity phenotypes (pmc.ncbi.nlm.nih.gov). In mammals, a striking study found that overexpressing MED13 in mouse hearts caused the animals to become resistant to diet-induced obesity, apparently by increasing cardiac-derived endocrine signals that boost metabolism (pmc.ncbi.nlm.nih.gov). Conversely, loss of MED13 in heart led to reduced metabolic rate and obesity in mice (pmc.ncbi.nlm.nih.gov). Given MED13L’s overlap in function, it likely participates in the same regulatory axis. In line with this, the Mediator MED13/MED13L subunits are emerging as key regulators of cardiac metabolism and are being investigated as potential therapeutic targets for metabolic syndrome and heart failure (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Cell Cycle Control and Signaling Pathways

Beyond development, MED13L plays an important role in fundamental cellular processes such as the cell cycle and signal-dependent gene regulation. A notable example is the Retinoblastoma (Rb)/E2F pathway that governs the G1-to-S phase cell cycle transition. In an oncogenesis context, Angus et al. (Oncogene 2012) discovered that MED13L is a crucial co-factor for Rb-mediated cell cycle arrest (pmc.ncbi.nlm.nih.gov). Rb protein ordinarily halts cell division by binding E2F transcription factors and repressing E2F-target genes (like cyclins and replication enzymes). Angus and colleagues performed a shRNA screen for factors required for Rb’s growth-suppressive function and found multiple Mediator subunits – prominently MED13L – to be necessary (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They demonstrated that knocking down MED13L allows cells to bypass Rb-induced senescence: even when Rb was activated, cells lacking MED13L failed to fully repress E2F target genes and continued cycling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Specifically, without MED13L, the expression of cyclin A and other cell-cycle genes could not be completely silenced by Rb, whereas in normal cells Rb caused cyclin A levels to drop and cells to exit the cell cycle (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus, MED13L is required for the “total” repression of cell-cycle gene transcription under Rb’s command (pmc.ncbi.nlm.nih.gov). This finding makes sense in light of Mediator’s role: Rb recruits chromatin modifiers and likely Mediator (via MED13L) to shut down E2F-responsive promoters. If MED13L (or the CDK8 module) is absent, Rb cannot assemble the full corepressor complex needed for durable gene silencing. This places MED13L as a potential tumor suppressor partner – indeed, the inability to arrest growth when MED13L is low could contribute to uncontrolled proliferation. While MED13L itself is not frequently mutated in cancers, the Fbw7 pathway that regulates MED13L is commonly disrupted in tumors (genesdev.cshlp.org) (genesdev.cshlp.org). It’s speculated that high MED13L levels (due to Fbw7 loss) might enforce a transcriptionally repressive state that selects for cells to bypass Rb in other ways, or that alterations in Mediator subunits could disturb normal cell-cycle checkpoints (genesdev.cshlp.org) (pmc.ncbi.nlm.nih.gov). In any case, the Rb/E2F study underscored MED13L’s role in signal-dependent transcriptional repression** in addition to its coactivator functions.

MED13L is also linked to major developmental signaling pathways. In particular, it has been implicated in the regulation of Wnt/β-catenin and Sonic Hedgehog (SHH) pathway target genes at the transcription level (www.genecards.org). The UniProt database notes that MED13L “may specifically regulate transcription of targets of the Wnt and SHH signaling pathways” (www.genecards.org). This is supported by genetic studies in model organisms: Mediator kinase module components (MED12-MED13 and by extension MED13L) have been shown to interact with Wnt signaling. For example, in zebrafish and Xenopus embryos, disruption of Mediator subunits causes Wnt pathway phenotypes, and in Drosophila the MED12/MED13 orthologs modulate Wingless (Wnt) target gene expression (www.genecards.org) (pmc.ncbi.nlm.nih.gov). Likewise, connections to the Hedgehog pathway were noted – a 2014 study found that certain MED12 mutations (in a related complex) led to dysregulated GLI3 (Hedgehog effector) activity (pubmed.ncbi.nlm.nih.gov). MED13L’s role in these pathways is likely context-dependent, but as a part of the CDK8 module, it can act as a transcriptional attenuator: the CDK8 module is known to transiently repress Wnt target genes to prevent inappropriate activation (www.genecards.org). For instance, during embryogenesis, β-catenin-driven genes might require Mediator with CDK8 (and MED13L) to keep them off until a Wnt signal is sufficiently strong to remove the module and allow full transcription. This model is supported by evidence that Mediator’s kinase module broadly constrains developmental gene activation, ensuring signaling outputs are properly timed. In summary, MED13L is a nexus where multiple signaling pathways (cell cycle, Wnt, SHH, nuclear receptors) intersect with the transcription machinery. By integrating these signals, MED13L helps decide which genes are transcribed in response to developmental cues and growth control signals.

Clinical Significance and Ongoing Research

Given its fundamental role in transcription, it is not surprising that MED13L is indispensable for normal human development. Heterozygous loss-of-function mutations in MED13L cause a distinctive neurodevelopmental disorder now known as MED13L syndrome (also called MED13L haploinsufficiency syndrome). This condition is inherited in an autosomal dominant manner (often arising de novo) and is characterized by global developmental delay, moderate to severe intellectual disability, severe speech impairment, and mild dysmorphic facial features (pubmed.ncbi.nlm.nih.gov). Many patients also have hypotonia (low muscle tone) and motor delays; a subset present with congenital heart defects or other anomalies (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). As of 2023, over 100 diagnosed individuals with pathogenic MED13L variants have been reported in the medical literature (www.ncbi.nlm.nih.gov). The spectrum of defects can be broad. For example, some individuals have autism spectrum behaviors, others have limb or eye abnormalities, and about 30–40% have structural heart defects (commonly septal defects or TGA) (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Intriguingly, there are also cases of MED13L duplications causing clinical issues, emphasizing that precise gene dosage is critical (pmc.ncbi.nlm.nih.gov). At the molecular level, most MED13L syndrome mutations are predicted to result in haploinsufficiency – e.g. frameshift or nonsense mutations that truncate the protein, or splice-site changes that disrupt the mRNA (pmc.ncbi.nlm.nih.gov). A recent report (J Med Genet, 2024) described splice-site variants in MED13L exon 7 that lead to intron retention and a premature stop codon, confirming loss-of-function as the disease mechanism (pmc.ncbi.nlm.nih.gov). The clear link between insufficient MED13L and developmental pathology underscores the gene’s importance: as demonstrated in mice, one functional copy is not enough for full neurologic and cardiac development (pmc.ncbi.nlm.nih.gov).

There is growing interest in translational research for MED13L-related disorder and in Mediator kinase module targets in general. From a clinical standpoint, genetic testing for MED13L mutations is now a part of many developmental delay and congenital heart defect diagnostic panels (www.ncbi.nlm.nih.gov). Early diagnosis allows for intervention services and cardiac monitoring where needed. Additionally, understanding MED13L’s function has suggested some therapeutic angles. Because MED13L influences metabolic and cardiac gene networks, researchers have speculated about modifying its activity to treat disease. For instance, small-molecule modulators of the CDK8/Cdk19 kinase (part of the same module) are being explored in cancer trials, and similar strategies could be considered to adjust Mediator activity in metabolic or cardiac conditions (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). A 2023 review noted that targeting pathways regulated by MED13L – such as nuclear receptor signaling – or developing compounds to compensate for MED13/L mutations could have therapeutic benefit for dilated cardiomyopathy or heart defects (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This is uncharted territory but highlights the potential of MED13L as a drug target. In terms of real-world applications, one immediate area is using MED13L and its network as biomarkers. Because MED13L and MED13 are central to cardiac metabolism, they might serve as early indicators of heart failure or cardiomyopathy risk. Schiano et al. (2023) suggest that evaluating MED13L-regulated gene signatures could improve the precision of cardiovascular disease diagnosis and management (pmc.ncbi.nlm.nih.gov).

Meanwhile, the MED13L patient community and scientists are actively collaborating. A patient-led organization, the MED13L Syndrome Foundation, was established to accelerate research. In 2023, the foundation, together with clinical experts, published a Strategic Research Plan (SRP) to map out priorities for understanding and treating MED13L syndrome (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This plan reviews known patient data, identifies gaps (for instance, the need for animal models – which has been partly addressed by the new Med13l knockout mouse), and outlines steps toward preclinical therapy development (pmc.ncbi.nlm.nih.gov). Key goals include developing outcome measures for future clinical trials and exploring gene therapy or RNA-based approaches to restore MED13L function. The SRP is a “living resource” that will guide researchers and drug developers in the coming years (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Although no specific treatment exists yet for MED13L syndrome, this organized effort is paving the way for possible interventions – whether via gene therapy (e.g. delivering a functional MED13L gene) or pharmacologically targeting pathways downstream of MED13L.

In summary, MED13L is a master regulator of transcription with broad influence on human development and physiology. It exemplifies how a single transcriptional cofactor can impact multiple organ systems – brain, heart, muscle – by controlling gene expression programs. Cutting-edge research from 2023–2024 has shed light on its molecular mechanics (such as the IDR “switch” for Mediator activity) and its in vivo roles (from neuron formation to heart muscle maintenance). These advances not only deepen our understanding of fundamental biology but also inform clinical strategies. MED13L’s involvement in critical pathways makes it a compelling subject for ongoing research, with the hope that unraveling its function will lead to targeted therapies for the syndromic disorder and perhaps other conditions (like heart failure and metabolic diseases) where Mediator dysfunction plays a part. As one recent review emphasized, dysregulation of Mediator subunits like MED13L lies at the crossroads of developmental disorders and common diseases – thus efforts to comprehend and modulate MED13L function could have far-reaching biomedical impacts (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Citations

1. AnnotationURLCitation(end_index=476, start_index=316, title='MED13L Gene - GeneCards | MD13L Protein | MD13L Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=MED13L#:~:text=Component%20of%20the%20Mediator%20complex%2C,%28%20MD13L_HUMAN%2CQ71F56')
2. AnnotationURLCitation(end_index=872, start_index=712, title='MED13L Gene - GeneCards | MD13L Protein | MD13L Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=MED13L#:~:text=Component%20of%20the%20Mediator%20complex%2C,%28%20MD13L_HUMAN%2CQ71F56')
3. AnnotationURLCitation(end_index=1295, start_index=1139, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=roles%20in%20regulating%20Mediator%20function,is%20limited%20to%20a%20study')
4. AnnotationURLCitation(end_index=1676, start_index=1408, title='Mutual Exclusivity of MED12/MED12L, MED13/13L, and CDK8/19 Paral', type='url_citation', url='https://www.longdom.org/open-access/mutual-exclusivity-of-med12med12l-med1313l-and-cdk819paralogs-revealed-within-the-cdkmediator-kinase-module-33208.html#:~:text=larger%20complex%20containing%20the%20CDK8,isolate%20each%20kinase%20module%20member')
5. AnnotationURLCitation(end_index=1990, start_index=1860, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=complex,and%20therapeutic%20target%20in%20the')
6. AnnotationURLCitation(end_index=2362, start_index=2192, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=MED13%2C%20MED13L%2C%20MED15%2C%20and%20MED23,rationale%20for%20focusing%20on%20these')
7. AnnotationURLCitation(end_index=2493, start_index=2363, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=complex,and%20therapeutic%20target%20in%20the')
8. AnnotationURLCitation(end_index=3206, start_index=3056, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=and%20Roeder%202005%20%29,CDK8%20module%20plays%20multiple%20distinct')
9. AnnotationURLCitation(end_index=3556, start_index=3406, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=and%20Roeder%202005%20%29,CDK8%20module%20plays%20multiple%20distinct')
10. AnnotationURLCitation(end_index=4026, start_index=3870, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=roles%20in%20regulating%20Mediator%20function,is%20limited%20to%20a%20study')
11. AnnotationURLCitation(end_index=4335, start_index=4151, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=that%20Fbw7%2C%20a%20tumor%20suppressor,regulating%20CDK8%20module%E2%80%93Mediator%20association%20and')
12. AnnotationURLCitation(end_index=4696, start_index=4512, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=that%20Fbw7%2C%20a%20tumor%20suppressor,regulating%20CDK8%20module%E2%80%93Mediator%20association%20and')
13. AnnotationURLCitation(end_index=4858, start_index=4697, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=Here%2C%20we%20demonstrate%20that%20the,Fbw7%20likely%20represents%20a%20general')
14. AnnotationURLCitation(end_index=5218, start_index=5034, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=that%20Fbw7%2C%20a%20tumor%20suppressor,regulating%20CDK8%20module%E2%80%93Mediator%20association%20and')
15. AnnotationURLCitation(end_index=5618, start_index=5434, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=that%20Fbw7%2C%20a%20tumor%20suppressor,regulating%20CDK8%20module%E2%80%93Mediator%20association%20and')
16. AnnotationURLCitation(end_index=5948, start_index=5787, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=Here%2C%20we%20demonstrate%20that%20the,Fbw7%20likely%20represents%20a%20general')
17. AnnotationURLCitation(end_index=6505, start_index=6335, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=MED13%2C%20MED13L%2C%20MED15%2C%20and%20MED23,rationale%20for%20focusing%20on%20these')
18. AnnotationURLCitation(end_index=6865, start_index=6665, title='An intrinsically disordered region in MED13 turns Mediator on/off on cue - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S1097276524006257#:~:text=Complementary%20studies%20by%20Zhao%20et%C2%A0al.,transcription%20activation%20on%20and%20off')
19. AnnotationURLCitation(end_index=7292, start_index=7092, title='An intrinsically disordered region in MED13 turns Mediator on/off on cue - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S1097276524006257#:~:text=Complementary%20studies%20by%20Zhao%20et%C2%A0al.,transcription%20activation%20on%20and%20off')
20. AnnotationURLCitation(end_index=7665, start_index=7465, title='An intrinsically disordered region in MED13 turns Mediator on/off on cue - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S1097276524006257#:~:text=Complementary%20studies%20by%20Zhao%20et%C2%A0al.,transcription%20activation%20on%20and%20off')
21. AnnotationURLCitation(end_index=8442, start_index=8242, title='An intrinsically disordered region in MED13 turns Mediator on/off on cue - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S1097276524006257#:~:text=Complementary%20studies%20by%20Zhao%20et%C2%A0al.,transcription%20activation%20on%20and%20off')
22. AnnotationURLCitation(end_index=9059, start_index=8888, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=reversibly%20associates%20with%20Mediator%20to,CDK8%20module%20plays%20multiple%20distinct')
23. AnnotationURLCitation(end_index=9404, start_index=9233, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=reversibly%20associates%20with%20Mediator%20to,CDK8%20module%20plays%20multiple%20distinct')
24. AnnotationURLCitation(end_index=10119, start_index=9973, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=In%20addition%20to%20mediator%20components%2C,Complementation')
25. AnnotationURLCitation(end_index=11051, start_index=10904, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=mechanisms%20remain%20largely%20elusive,cell%20transcriptomics')
26. AnnotationURLCitation(end_index=11231, start_index=11052, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=simplified%20neuronal%20morphology%20in%20the,reveal%20that%20MED13L%20orchestrates%20cortical')
27. AnnotationURLCitation(end_index=11464, start_index=11317, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=mechanisms%20remain%20largely%20elusive,cell%20transcriptomics')
28. AnnotationURLCitation(end_index=11757, start_index=11610, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=mechanisms%20remain%20largely%20elusive,cell%20transcriptomics')
29. AnnotationURLCitation(end_index=12197, start_index=12050, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=mechanisms%20remain%20largely%20elusive,cell%20transcriptomics')
30. AnnotationURLCitation(end_index=12604, start_index=12425, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=simplified%20neuronal%20morphology%20in%20the,reveal%20that%20MED13L%20orchestrates%20cortical')
31. AnnotationURLCitation(end_index=12927, start_index=12778, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=dendrite%20development,in%20the%20developing%20cerebral%20cortex')
32. AnnotationURLCitation(end_index=13313, start_index=13164, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=dendrite%20development,in%20the%20developing%20cerebral%20cortex')
33. AnnotationURLCitation(end_index=13582, start_index=13425, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=exhibit%20neonatal%20lethality%20accompanied%20by,cell%20transcriptomics')
34. AnnotationURLCitation(end_index=13740, start_index=13583, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=match%20at%20L714%20In%20addition,These%20dendritic%20abnormalities%20in')
35. AnnotationURLCitation(end_index=14380, start_index=14230, title='Redefining the MED13L syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25758992/#:~:text=disability%20%28ID%29,in%20combination%20with%20articulatory%20deficits')
36. AnnotationURLCitation(end_index=15133, start_index=15005, title='MED13L Gene - GeneCards | MD13L Protein | MD13L Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=MED13L#:~:text=,provided%20by%20RefSeq%2C%20Jul%202010')
37. AnnotationURLCitation(end_index=15289, start_index=15134, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=match%20at%20L466%20MED13L%20has,gene%20has%20been%20associated%20with')
38. AnnotationURLCitation(end_index=15594, start_index=15453, title='Redefining the MED13L syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25758992/#:~:text=through%20DNA,profound%20language%20impairment%2C%20often%20in')
39. AnnotationURLCitation(end_index=15926, start_index=15776, title='Redefining the MED13L syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25758992/#:~:text=disability%20%28ID%29,in%20combination%20with%20articulatory%20deficits')
40. AnnotationURLCitation(end_index=16437, start_index=16346, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=MED13L')
41. AnnotationURLCitation(end_index=16598, start_index=16438, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=MED13L%20has%20been%20implicated%20in,gene%20has%20been%20associated%20with')
42. AnnotationURLCitation(end_index=17003, start_index=16843, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=MED13L%20has%20been%20implicated%20in,gene%20has%20been%20associated%20with')
43. AnnotationURLCitation(end_index=17308, start_index=17148, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=MED13L%20has%20been%20implicated%20in,gene%20has%20been%20associated%20with')
44. AnnotationURLCitation(end_index=17961, start_index=17829, title='Med13 and Med13L: Critical redundant players in basal cardiac function and gene expression - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12451381/#:~:text=We%20investigated%20the%20overlap%20of,of%20the')
45. AnnotationURLCitation(end_index=18131, start_index=17962, title='Med13 and Med13L: Critical redundant players in basal cardiac function and gene expression - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12451381/#:~:text=The%2091%20overlapping%20genes%20between,highlight%20the%20redundant%20function%20of')
46. AnnotationURLCitation(end_index=18485, start_index=18347, title='Med13 and Med13L: Critical redundant players in basal cardiac function and gene expression - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12451381/#:~:text=We%20then%20performed%20a%20survival,This%20indicates')
47. AnnotationURLCitation(end_index=18905, start_index=18742, title='Med13 and Med13L: Critical redundant players in basal cardiac function and gene expression - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12451381/#:~:text=they%20are%20two%20distinct%20model,respective%20subunit%20results%20in%20gene')
48. AnnotationURLCitation(end_index=19075, start_index=18906, title='Med13 and Med13L: Critical redundant players in basal cardiac function and gene expression - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12451381/#:~:text=The%2091%20overlapping%20genes%20between,highlight%20the%20redundant%20function%20of')
49. AnnotationURLCitation(end_index=19430, start_index=19298, title='Med13 and Med13L: Critical redundant players in basal cardiac function and gene expression - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12451381/#:~:text=We%20investigated%20the%20overlap%20of,of%20the')
50. AnnotationURLCitation(end_index=19565, start_index=19431, title='Med13 and Med13L: Critical redundant players in basal cardiac function and gene expression - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12451381/#:~:text=four%20Mediator%20cardiac%20knockouts%20%28Fig,We')
51. AnnotationURLCitation(end_index=19810, start_index=19678, title='Med13 and Med13L: Critical redundant players in basal cardiac function and gene expression - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12451381/#:~:text=We%20investigated%20the%20overlap%20of,of%20the')
52. AnnotationURLCitation(end_index=19980, start_index=19811, title='Med13 and Med13L: Critical redundant players in basal cardiac function and gene expression - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12451381/#:~:text=The%2091%20overlapping%20genes%20between,highlight%20the%20redundant%20function%20of')
53. AnnotationURLCitation(end_index=20587, start_index=20416, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=The%20role%20of%20cardiac%20MED13L,therapeutic%20target%20for%20addressing%20metabolic')
54. AnnotationURLCitation(end_index=21363, start_index=21261, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=,Google%20Scholar')
55. AnnotationURLCitation(end_index=21535, start_index=21364, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=The%20role%20of%20cardiac%20MED13L,therapeutic%20target%20for%20addressing%20metabolic')
56. AnnotationURLCitation(end_index=21801, start_index=21680, title='Heart- and muscle-derived signaling system dependent on MED13 and Wingless controls obesity in Drosophila - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4084481/#:~:text=Heart,Duby%20%5E%7B1%7D%2C%20Eric%20N')
57. AnnotationURLCitation(end_index=22196, start_index=22025, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=The%20role%20of%20cardiac%20MED13L,therapeutic%20target%20for%20addressing%20metabolic')
58. AnnotationURLCitation(end_index=22454, start_index=22283, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=The%20role%20of%20cardiac%20MED13L,therapeutic%20target%20for%20addressing%20metabolic')
59. AnnotationURLCitation(end_index=22927, start_index=22756, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=The%20role%20of%20cardiac%20MED13L,therapeutic%20target%20for%20addressing%20metabolic')
60. AnnotationURLCitation(end_index=23089, start_index=22928, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=disorders%20and%20specific%20CVDs,NRs%20signaling%20and%20RNA%20modification')
61. AnnotationURLCitation(end_index=23683, start_index=23543, title='A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3707121/#:~:text=transcription,genes%2C%20and%20cell%20cycle%20inhibition')
62. AnnotationURLCitation(end_index=24204, start_index=24016, title='A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3707121/#:~:text=Shading%20indicates%20gene%20products%20identifed,MED27%2C%20MED13L%2C%20DNAJA1%2C%20ZCCHC10%2C%20TARDBP')
63. AnnotationURLCitation(end_index=24335, start_index=24205, title='A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3707121/#:~:text=MED13L%20is%20a%20functional%20Rb%2FE2F,factor')
64. AnnotationURLCitation(end_index=24683, start_index=24543, title='A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3707121/#:~:text=transcription,genes%2C%20and%20cell%20cycle%20inhibition')
65. AnnotationURLCitation(end_index=24850, start_index=24684, title='A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3707121/#:~:text=requirement%20for%20MED13L%20in%20Rb%2FE2F,selected%20with%20hygromycin%20for%2019')
66. AnnotationURLCitation(end_index=25236, start_index=25071, title='A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3707121/#:~:text=To%20determine%20whether%20MED13L%20played,inhibition%20of%20DNA%20synthesis%20by')
67. AnnotationURLCitation(end_index=25411, start_index=25237, title='A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3707121/#:~:text=This%20suggested%20that%20the%20depletion,contrast%2C%20cells%20transfected%20with%20siRNA')
68. AnnotationURLCitation(end_index=25659, start_index=25519, title='A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3707121/#:~:text=transcription,genes%2C%20and%20cell%20cycle%20inhibition')
69. AnnotationURLCitation(end_index=26372, start_index=26240, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=match%20at%20L35%20up%20to,2007%29%20and%20degrades')
70. AnnotationURLCitation(end_index=26534, start_index=26373, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=Here%2C%20we%20demonstrate%20that%20the,Fbw7%20likely%20represents%20a%20general')
71. AnnotationURLCitation(end_index=26966, start_index=26782, title='The SCF–Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator', type='url_citation', url='https://genesdev.cshlp.org/content/27/2/151.long#:~:text=that%20Fbw7%2C%20a%20tumor%20suppressor,regulating%20CDK8%20module%E2%80%93Mediator%20association%20and')
72. AnnotationURLCitation(end_index=27107, start_index=26967, title='A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3707121/#:~:text=transcription,genes%2C%20and%20cell%20cycle%20inhibition')
73. AnnotationURLCitation(end_index=27634, start_index=27478, title='MED13L Gene - GeneCards | MD13L Protein | MD13L Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=MED13L#:~:text=This%20subunit%20may%20specifically%20regulate,MD13L_HUMAN%2CQ71F56')
74. AnnotationURLCitation(end_index=27922, start_index=27766, title='MED13L Gene - GeneCards | MD13L Protein | MD13L Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=MED13L#:~:text=This%20subunit%20may%20specifically%20regulate,MD13L_HUMAN%2CQ71F56')
75. AnnotationURLCitation(end_index=28477, start_index=28306, title='MED13L Gene - GeneCards | MD13L Protein | MD13L Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=MED13L#:~:text=Component%20of%20the%20Mediator%20complex%2C,the%20Wnt%20signaling%20pathway%20and')
76. AnnotationURLCitation(end_index=28599, start_index=28478, title='Heart- and muscle-derived signaling system dependent on MED13 and Wingless controls obesity in Drosophila - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4084481/#:~:text=Heart,Duby%20%5E%7B1%7D%2C%20Eric%20N')
77. AnnotationURLCitation(end_index=28914, start_index=28785, title='MED12 mutations link intellectual disability syndromes with dysregulated GLI3-dependent Sonic Hedgehog signaling - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/23091001/#:~:text=GLI3,subsequently%20with%20an%20internal%20control')
78. AnnotationURLCitation(end_index=29318, start_index=29158, title='MED13L Gene - GeneCards | MD13L Protein | MD13L Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=MED13L#:~:text=Component%20of%20the%20Mediator%20complex%2C,%28%20MD13L_HUMAN%2CQ71F56')
79. AnnotationURLCitation(end_index=30755, start_index=30605, title='Redefining the MED13L syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25758992/#:~:text=disability%20%28ID%29,in%20combination%20with%20articulatory%20deficits')
80. AnnotationURLCitation(end_index=31038, start_index=30897, title='Redefining the MED13L syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25758992/#:~:text=through%20DNA,profound%20language%20impairment%2C%20often%20in')
81. AnnotationURLCitation(end_index=31186, start_index=31039, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=aortic%20coarctation,intron%2C%20leading%20to%20a%20frameshift')
82. AnnotationURLCitation(end_index=31458, start_index=31310, title='MED13L Syndrome - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK613517/#:~:text=MED13L%20Syndrome%20,the%20phenotypic%20features%20associated%20with')
83. AnnotationURLCitation(end_index=31820, start_index=31679, title='Redefining the MED13L syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25758992/#:~:text=through%20DNA,profound%20language%20impairment%2C%20often%20in')
84. AnnotationURLCitation(end_index=31981, start_index=31821, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=MED13L%20has%20been%20implicated%20in,gene%20has%20been%20associated%20with')
85. AnnotationURLCitation(end_index=32279, start_index=32119, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=MED13L%20has%20been%20implicated%20in,gene%20has%20been%20associated%20with')
86. AnnotationURLCitation(end_index=32641, start_index=32494, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=aortic%20coarctation,intron%2C%20leading%20to%20a%20frameshift')
87. AnnotationURLCitation(end_index=32985, start_index=32838, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=aortic%20coarctation,intron%2C%20leading%20to%20a%20frameshift')
88. AnnotationURLCitation(end_index=33343, start_index=33196, title='Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331956/#:~:text=mechanisms%20remain%20largely%20elusive,cell%20transcriptomics')
89. AnnotationURLCitation(end_index=33731, start_index=33637, title='MED13L Syndrome - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/sites/books/n/gene/med13l/#:~:text=,The')
90. AnnotationURLCitation(end_index=34451, start_index=34280, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=The%20role%20of%20cardiac%20MED13L,therapeutic%20target%20for%20addressing%20metabolic')
91. AnnotationURLCitation(end_index=34613, start_index=34452, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=disorders%20and%20specific%20CVDs,NRs%20signaling%20and%20RNA%20modification')
92. AnnotationURLCitation(end_index=35028, start_index=34857, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=The%20role%20of%20cardiac%20MED13L,therapeutic%20target%20for%20addressing%20metabolic')
93. AnnotationURLCitation(end_index=35190, start_index=35029, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=disorders%20and%20specific%20CVDs,NRs%20signaling%20and%20RNA%20modification')
94. AnnotationURLCitation(end_index=35852, start_index=35682, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=match%20at%20L494%20In%20addition%2C,homeostasis%20and%20gene%20regulation%2C%20these')
95. AnnotationURLCitation(end_index=36382, start_index=36215, title='The MED13L Foundation strategic research plan: a roadmap to the future - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11605767/#:~:text=Scientific%20literature%20is%20reviewed%20in,SRP%20becomes%20a%20living%20resource')
96. AnnotationURLCitation(end_index=36521, start_index=36383, title='The MED13L Foundation strategic research plan: a roadmap to the future - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11605767/#:~:text=The%20MED13L%20Foundation%20strategic%20research,plan')
97. AnnotationURLCitation(end_index=36917, start_index=36750, title='The MED13L Foundation strategic research plan: a roadmap to the future - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11605767/#:~:text=Scientific%20literature%20is%20reviewed%20in,SRP%20becomes%20a%20living%20resource')
98. AnnotationURLCitation(end_index=37358, start_index=37170, title='The MED13L Foundation strategic research plan: a roadmap to the future - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11605767/#:~:text=responsible%20for%20growing%20the%20understanding,reach%20their%20organizational%20goals%2C%20including')
99. AnnotationURLCitation(end_index=37497, start_index=37359, title='The MED13L Foundation strategic research plan: a roadmap to the future - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11605767/#:~:text=The%20MED13L%20Foundation%20strategic%20research,plan')
100. AnnotationURLCitation(end_index=39047, start_index=38917, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=complex,and%20therapeutic%20target%20in%20the')
101. AnnotationURLCitation(end_index=39219, start_index=39048, title='Mediator complex: update of key insights into transcriptional regulation of ancestral framework and its role in cardiovascular diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12183845/#:~:text=The%20role%20of%20cardiac%20MED13L,therapeutic%20target%20for%20addressing%20metabolic')